AbbVie Inc. [NYSE: ABBV] closed the trading session at $108.67 on 12/09/20. The day’s price range saw the stock hit a low of $107.63, while the highest price level was $109.15. The company report on December 9, 2020 that Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis.
– Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe ulcerative colitis.
– All ranked secondary endpoints, including clinical, endoscopic and histologic outcomes, were met.
The stocks have a year to date performance of 22.74 percent and weekly performance of 3.51 percent. The stock has been moved at 17.79 percent over the last six months. The stock has performed 14.25 percent around the most recent 30 days and changed 21.22 percent over the most recent 3-months.
If compared to the average trading volume of 8.22M shares, ABBV reached to a volume of 6984624 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AbbVie Inc. [ABBV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $112.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Bernstein have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 10, 2020. While these analysts kept the previous recommendation, Berenberg raised their target price to Hold. The new note on the price target was released on September 29, 2020, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $115, while Atlantic Equities analysts kept a Overweight rating on ABBV stock.
The Average True Range (ATR) for AbbVie Inc. is set at 2.40, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.61. The Price to Book ratio for the last quarter was 12.59, with the Price to Cash per share for the same quarter was set at 4.61. Price to Free Cash Flow for ABBV in the course of the last twelve months was 23.08 with Quick ratio for the last quarter at 0.80.
ABBV stock trade performance evaluation
AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.51. With this latest performance, ABBV shares gained by 14.25% in over the last four-week period, additionally plugging by 17.79% over the last 6 months – not to mention a rise of 25.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 74.24, with the RSI for the last a single of trading hit 77.72, and the three-weeks RSI is set at 72.27 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 93.39, while it was recorded at 106.84 for the last single week of trading, and 90.25 for the last 200 days.
AbbVie Inc. [ABBV]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +41.83 and a Gross Margin at +77.14. AbbVie Inc.’s Net Margin is presently recorded at +23.57.
Return on Total Capital for ABBV is now 30.66, given the latest momentum, and Return on Invested Capital for the company is 19.22. Additionally, ABBV Total Debt to Total Capital is recorded at 113.87, with Total Debt to Total Assets ending up at 75.28.
Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $261,400 per employee. Receivables Turnover for the company is 5.89 with a Total Asset Turnover recorded at a value of 0.45.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.
Earnings per share (EPS) analysis for AbbVie Inc. [ABBV] stock
With the latest financial reports released by the company, AbbVie Inc. posted 2.21/share EPS, while the average EPS was predicted by analysts to be reported at 2.19/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 9.27%.
AbbVie Inc. [ABBV]: Insider Ownership positions
There are presently around $131,867 million, or 70.20% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 144,334,850, which is approximately -2.071% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 122,016,637 shares of the stock with an approximate value of $13.26 billion in ABBV stocks shares; and STATE STREET CORP, currently with $8.5 billion in ABBV stock with ownership of nearly -1.902% of the company’s market capitalization.
Positions in AbbVie Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,180 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 60,052,060 shares. Additionally, 1,054 investors decreased positions by around 79,387,443 shares, while 279 investors held positions by with 1,074,026,864 shares. The mentioned changes placed institutional holdings at 1,213,466,367 shares, according to the latest SEC report filing. ABBV stock had 107 new institutional investments in for a total of 22,897,360 shares, while 131 institutional investors sold positions of 5,583,943 shares during the same period.